NCT04840615 2024-02-02
Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
Clinical Trials
25 trialsNCT03233724 2023-05-31
Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02859415 2022-04-05
Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT03644550 2021-12-02
Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01143545 2020-03-03
Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01624090 2019-12-30
Mithramycin for Lung, Esophagus, and Other Chest Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00094978 2019-12-12
Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01258868 2019-12-03
Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT03436732 2019-11-22
Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01583686 2019-10-14
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01445392 2018-08-03
SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01861301 2016-10-24
Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00112684 2014-02-24
Alvocidib in Treating Patients With Locally Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00436579 2014-02-24
Sorafenib in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00701298 2014-02-24
Decitabine With or Without Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00369200 2013-12-11
AFP464 in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00012194 2013-07-09
7-hydroxystaurosporine and Cisplatin in Treating Patients With Advanced Malignant Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00009958 2013-05-16
Vaccine Therapy With or Without Sargramostim in Treating Patients With Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00066625 2013-02-01
Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00010205 2013-01-25
Benzoylphenylurea in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00030693 2013-01-24
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00049088 2013-01-24
Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00086970 2013-01-24
Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00028561 2013-01-17
BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00028782 2013-01-16
EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
National Cancer Institute (NCI)
Phase NA Terminated